Tempus AI (NASDAQ:TEM) Trading 0.1% Higher – Still a Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price rose 0.1% during mid-day trading on Friday . The stock traded as high as $55.00 and last traded at $54.87. Approximately 5,948,954 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 8,785,969 shares. The stock had previously closed at $54.84.

Wall Street Analyst Weigh In

TEM has been the topic of several research reports. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital dropped their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Finally, Bank of America lifted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Tempus AI Trading Down 2.5 %

The business has a fifty day moving average price of $44.38 and a two-hundred day moving average price of $47.46. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total value of $792,200.00. Following the transaction, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at $38,914,527.62. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,300,761 shares of company stock worth $51,271,197 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI during the third quarter worth $30,000. FNY Investment Advisers LLC purchased a new position in shares of Tempus AI during the fourth quarter worth $67,000. Vestor Capital LLC purchased a new position in shares of Tempus AI during the third quarter worth $153,000. Stifel Financial Corp purchased a new position in shares of Tempus AI during the third quarter worth $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Tempus AI during the third quarter worth $258,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.